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Abstract
Objective: This two-site randomised trial compared the effectiveness of a voluntary sector-led, community-based
diabetes prevention programme to a waiting-list control group at 6 months, and included an observational follow-
up of the intervention arm to 12 months.
Methods: Adults aged 18–75 years at increased risk of developing type 2 diabetes due to elevated blood glucose
and being overweight were recruited from primary care practices at two UK sites, with data collected in
participants’ homes or community venues. Participants were randomised using an online central allocation service.
The intervention, comprising the prototype “Living Well, Taking Control” (LWTC) programme, involved four weekly
two-hour group sessions held in local community venues to promote changes in diet and physical activity, plus
planned follow-up contacts at two, three, six, nine and 12 months alongside 5 hours of additional activities/classes.
Waiting list controls received usual care for 6 months before accessing the programme. The primary outcome was
weight loss at 6 months. Secondary outcomes included glycated haemoglobin (HbA1c), blood pressure, physical
activity, diet, health status and well-being. Only researchers conducting analyses were blinded.
Results: The target sample of 314 participants (157 each arm) was largely representative of local populations,
including 44% men, 26% from ethnic minorities and 33% living in deprived areas. Primary outcome data were
available for 285 (91%) participants (141 intervention, 144 control). Between baseline and 6 months, intervention
participants on average lost more weight than controls (− 1.7 kg, 95% CI − 2.59 to − 0.85). Higher attendance was
associated with greater weight loss (− 3.0 kg, 95% CI − 4.5 to − 1.5). The prototype LWTC programme more than
doubled the proportion of participants losing > 5% of their body weight (21% intervention vs. 8% control, OR 2.83,
95% CI 1.36 to 5.90) and improved self-reported dietary behaviour and health status. There were no impacts on
HbA1c, blood pressure, physical activity and well-being at 6 months and, amongst intervention participants, few
further changes from six to 12-months (e.g. average weight re-gain 0.36 kg, 95% CI − 0.20 to 0.91). There were no
serious adverse events but four exercise-related injuries were reported in the intervention arm.
Conclusions: This voluntary sector-led diabetes prevention programme reached a broad spectrum of the
population and had modest effects on weight-related outcomes, but limited impacts on other diabetes risk factors.
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Background
Diabetes and its complications account for around 12%
of global health expenditure [1]. If recent trends con-
tinue, by 2040 over 600 million people worldwide will
have diabetes [1]. Prevention of type 2 diabetes is para-
mount to curb this growing health crisis [2, 3].
Drawing on international evidence from high quality tri-
als [4–6] and systematic reviews [7, 8], guidelines [3, 9, 10]
recommend intensive lifestyle interventions promoting
modest weight loss (e.g. 5% of body weight [9]) through
changes in diet and physical activity to prevent or delay
progression to diabetes in people at high risk of the condi-
tion. Without intervention, 30–50% of people with one or
more markers of non-diabetic hyperglycaemia [11], a state
of chronically raised blood glucose indicated by impaired
fasting glucose, impaired glucose tolerance, or raised
HbA1c (glycated haemoglobin of 42–47mmol/mol) [3],
will develop type 2 diabetes within 5 years [12]. Announced
in March 2015, the “Healthier You: NHS Diabetes Preven-
tion Programme” (NHS DPP) launched in 2016 to target
the estimated 11% of people across England with non-
diabetic hyperglycaemia [13], with more than 280,000
people referred as of September 2018 [14].
Despite roll-out of the NHS DPP, UK National Institute
for Health and Care Excellence (NICE) diabetes prevention
guidance [3] states that “evidence on both the short- and
long-term effectiveness and cost-effectiveness of translating
prevention trials into UK practice” (p.157) is still lacking. A
systematic review [15] reported that “real-world” diabetes
prevention interventions demonstrating greater adherence
to recommendations on intervention content [3] generated
higher levels of weight loss (up to 4 kg at 12months for the
most guideline-adherent). Preliminary data from the NHS
DPP [14] indicate a mean weight loss of 3.2 kg amongst the
half of participants who attended at least 60% of the
sessions, which is sufficient to affect diabetes risk [3, 5].
Cautious interpretation is warranted, however, because this
finding was based on a selective sub-group of participants,
without reference to a comparison group. Moreover, no
other UK community-based programmes [16–18] have
demonstrated weight loss at this level in controlled studies
with high levels of follow up.
Therefore, there remains a need for further, robust
evidence on the implementation and effectiveness of
pragmatic, guideline-based programmes in real-world
UK communities that differ from the intensive lifestyle-
based interventions studied in highly selected samples in
the original diabetes prevention efficacy trials [4, 6, 19].
This paper reports a trial providing such evidence for a
prototype version of “Living Well, Taking Control”
(LWTC), a community-based diabetes prevention
programme delivered by voluntary sector providers de-
signed to be compliant with UK guidance [2, 3] that fol-
lowing in depth evaluation of retention and outcomes,
as well as participant feedback, was subsequently
adapted for delivery in the NHS DPP [20]. The voluntary
sector is increasingly involved in delivering public health
and health services in England [21] and has the potential
to intervene at relatively low cost without employing
over-stretched NHS staff, and to engage hard-to-reach
communities [22]. These services are, however, rarely
subject to robust evaluation [22].
This Community-based Prevention of Diabetes (Com-
PoD) trial aimed to assess whether the prototype LWTC
programme was superior to usual care in promoting
weight loss (primary outcome), modifying other risk
factors (including HbA1c and physical activity) and im-
proving self-reported outcomes in adults at risk of type
2 diabetes at 6 months of follow up. It also assessed
whether any changes in outcomes amongst intervention
participants were maintained up to 12 months, and to
address concerns about the potential for such interven-
tions to widen health inequalities [23], explored potential
variations in effects across population subgroups.
Methods
Design
We conducted a two-site, randomised, superiority trial with
a parallel control arm, which is reported here in line with
CONSORT guidelines (see Fig. 1 and Additional file 1:
CONSORT checklist). Participants at two sites were indi-
vidually allocated in a 1:1 ratio to the prototype LWTC
programme (intervention), or a six-month, usual care wait-
ing list for the programme (control). We used a waiting list
control because the prototype LWTC programme was an
existing service that eligible participants could access
outside the trial, and it was deemed unethical and likely to
jeopardise trial recruitment to deny access beyond 6
months. We also conducted a 12-month observational
follow-up of intervention participants to assess mainten-
ance of any changes beyond the core contact sessions.
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Participants
Trial inclusion criteria mirrored existing programme eli-
gibility. From November 2014 to June 2015, general
practitioner (GP) practices searched patient records to
identify adults aged 18–75 years at high risk for type 2
diabetes due to elevated blood glucose (Fasting Plasma
Glucose 6.1–6.9 mmol/l [24], or HbA1c 42–47 mmol/
mol [3, 25] recorded within the past year) and body
mass index (BMI) ≥25 kg/m2 (≥23 for South Asians [3])
and less than 45 kg/m2. Participants resided in or around
Birmingham (the largest and most ethnically diverse
English city outside London) or Exeter (a small city in
rural south-west England).
We excluded participants who had a terminal illness,
an existing diagnosis or baseline HbA1c (≥48mmol/mol)
indicating type 2 diabetes [25], were participating in an-
other weight loss study, lacked capacity to give informed
consent or understand study procedures despite assist-
ance (e.g. due to dementia, severe learning disability),
were pregnant, or could not be weighed using standard
Fig. 1 Recruitment and flow of participants through the ComPoD trial and prototype LWTC programme
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scales. The programme otherwise aimed to include and
cater for people with low literacy, needing interpreters
or with mild-moderate mental health problems, learning
or physical disabilities.
Procedures
The programme providers or Local Clinical Research Net-
works approached GP practices in eligible areas. Participat-
ing practices mailed potential participants an invitation
providing brief information on the trial, a booklet on dia-
betes risk [26], a flyer on the prototype LWTC programme
and a postage-paid reply slip. Trial researchers, with assist-
ance from interpreters where requested, telephoned re-
spondents to check likely eligibility, discuss participation
and schedule an assessment. They then sent a full Partici-
pant Information Sheet and Consent Form. At an assess-
ment visit in the participant’s home or another convenient
location (e.g. university premises, GP practice), researchers
answered any questions, obtained written informed consent
and completed baseline measures, starting with BMI and
HbA1c to confirm eligibility. People indicating that they
wished to access the programme without participating in
the trial were referred to the providers and added to their
standard waiting list.
Intervention
The voluntary sector providers (Westbank in Exeter www.
westbank.org.uk, Health Exchange in Birmingham www.
healthexchange.org.uk) had collaboratively designed the
prototype LWTC programme, building on their previous
well-being and diabetes management programmes [27].
Delivery was supported by a detailed intervention manual
for programme facilitators and 40-page booklet summaris-
ing key information which participants used to document
their clinical measures, goals, plans, and reflections. As
documented in Additional file 2, these materials aimed to
ensure that the programme structure, content (e.g. inter-
active information on healthy eating recommendations, aer-
obic and muscle-strengthening physical activity, impact of
lifestyle on diabetes risk), behaviour change techniques used
(e.g. motivational interviewing, goal setting, action planning,
self-monitoring, engaging social support, problem-solving),
and delivery (e.g. staff were trained in using person-centred
counselling techniques to build empathy and assess
and enhance motivation with a focus on building the
perceived importance of, and confidence in, making
changes) reflected all 11 NICE recommendations for dia-
betes prevention interventions [3]. Fidelity of implementa-
tion was checked at one site, and as reported elsewhere
[28], found to be high. Participant satisfaction with the
programme is also reported elsewhere [29].
The “core” intervention comprised four, weekly, two-
hour sessions in groups of up to 12 participants (plus ac-
companying partners/supporters where desired) held in
local community venues and led by trained facilitators.
There were planned support contacts at two, three, six,
nine and 12 months, which in Exeter were mostly group-
based and in Birmingham mostly individual telephone
calls. The programme was also designed to offer partici-
pants 5 hours of additional classes or activities of their
choosing (e.g. exercise sessions, cooking classes). All
available data on attendance at group sessions and fol-
low up contacts were obtained from provider records at
the end of the study, however, attendance at additional
classes/activities had not been documented due to some
of these taking place outside the provider organisations
(e.g. walks in local communities) or being initiated by
participants (e.g. visits to the provider’s gym).
Control arm
Control participants went onto a six-month waiting list
for the programme during which time they continued
with routine care from their GP involving minimal or no
follow-up related to their diabetes risk.
Outcomes
Trained researchers, accompanied by an interpreter
where necessary (n = 8), assessed outcomes at baseline
and 6 months (mean 197 days) and, for intervention par-
ticipants only, after 12 months (mean 375 days).
The primary outcome was weight loss (kg) from base-
line to 6 months assessed using Tanita scales (model
BC-601). Secondary weight-related outcomes were
achievement of 3 and 5% weight loss, BMI (calculated
from weight, and height measured using a Seca 213
portable stadiometer), and waist circumference (mea-
sured using a Seca measuring tape 201 placed between
the uppermost border of the hip bone and the lower
border of the rib cage against the skin, or light clothing).
For these outcomes the average of two measurements,
or three if the first two were > 0.5 units apart, was used.
Other secondary objective outcomes were HbA1c,
assessed using a portable Alere Afinion AS100 Analyzer
to analyse capillary blood from a finger-prick, and blood
pressure measured from the left arm whilst seated over
bare skin or light clothing using an Omron 705IT moni-
tor. Physical activity was assessed using Actigraph
wGT3X accelerometers, which participants were asked
to wear on their waist for seven consecutive days and
were set to record activity counts in one-second epochs.
Participants also completed questionnaires routinely
used in the LWTC programme as part of an existing
before-after service evaluation [29]. These included the
short-version New Zealand Physical Activity Question-
naire [30] (data not reported here due to availability of
accelerometer data), a 27-item Fat and Fibre question-
naire [31] previously adapted for another diabetes pre-
vention study [32] to assess dietary behaviours related to
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fat and fibre intake, and the Short Warwick-Edinburgh
Mental Well-being Scale [33] to assess the frequency of
positive thoughts and feelings over the past 2 weeks.
Health status was assessed using the EuroQol EQ-5D [34]
and life satisfaction with a widely-used single item 1–10
rating scale [35]. Participants who, when contacted for
follow-up, wished to withdraw or were unavailable for
face-to-face assessment, were asked for their self-reported
weight. Socio-demographic (age, gender, ethnicity) and
socio-economic characteristics (employment status, edu-
cation level, Index of Multiple Deprivation derived from
postcodes), co-morbidities, prescribed medications and
co-interventions were recorded at baseline.
Sample size
The standard deviation for weight loss in other UK
community-based weight loss trials [36–38] is around 5.8
kg. To detect a minimum clinically important difference of
2.0 kg in weight loss [39] between arms, with 80% power
and a two-sided alpha of 5%, we needed 133 per group.
Allowing for 15% drop-out at 6 months based on our previ-
ous community-based weight loss studies [38, 40, 41], we
sought to recruit 156 participants per arm.
Randomisation and blinding
Participants were randomised at the end of their baseline
assessment by researchers accessing an internet-based
central allocation service developed and maintained by
the Peninsula Clinical Trials Unit. Randomisation was
stratified by site (Birmingham, Exeter) and a minimisa-
tion algorithm was used to balance the arms in terms of
age (≤54, 55–64, 65–75 years), gender and baseline BMI
(23–29.9, 30–36.9, 37–45 kg/m2), whilst maintaining a
stochastic element [42]. Given the nature of the inter-
vention and need for close liaison with the providers in
relation to programme delivery, it was not possible to
blind participants or researchers collecting data. The re-
mainder of the research team, including those conduct-
ing analyses, remained blinded until primary analyses
were complete.
Analyses
A detailed statistical analysis plan was developed and
agreed with the Trial Steering Committee including an
independent statistician, prior to analysis. Entry of all
primary outcome data and at least 20% of other data
were checked by a second researcher.
Raw accelerometer data were initially downloaded
using Actilife version 6.13.2 software then exported for
processing in R-package GGIR (version 1.2–8) [43]. Data
were analysed in one-second epochs with the first and
final one-hour periods removed. A standard deviation of
< 13mg and an acceleration range < 50mg on two axes
were used to detect periods of non-wear, with non-wear
periods calculated over 60 min using moving 15-min
increments [44]. Time spent in moderate-to-vigorous-
intensity physical activity overall, and as per guidelines
at the time the study was conducted [45], accumulated
in bouts of 10 min or more, was calculated using pub-
lished Euclidean Norm Minus One (ENMO; mg)
thresholds [46]. A valid day of measurement was de-
fined as at least 600 min of registered wear-time [47].
Participants with a minimum of four valid days of ac-
tivity including at least one weekend day were included
in analyses, with data extrapolated where necessary to
give estimates over 7 days.
Based on the intention-to-treat principle (i.e. analysis
according to original random allocation), primary and
secondary outcomes were compared between interven-
tion and control arms at 6 months using linear (for con-
tinuous outcomes) or logistic (for binary outcomes)
regression-based models in participants with complete
primary outcome data. The primary analysis adjusted for
baseline values of the outcome, stratification (site) and
minimisation variables (gender, age and baseline BMI).
Planned sensitivity analyses were also conducted with
additional adjustment for ethnicity as a prognostically
important variable that on visual inspection was identi-
fied as differing between arms at baseline.
Further sensitivity analyses examined the impact of
imputing missing six-month primary outcome data
(weight loss), using multiple imputation (assuming data
missing at random), baseline value carried forward
(commonly used in weight loss studies [36, 37]), and
best and worst case scenarios (e.g. no change assumed
for missing intervention cases and mean improvement
seen in control completers assumed for missing control
cases) [48]. For the primary outcome, we also conducted
the completer analysis with self-reported weight data for
the small number of participants unavailable for face-to-
face measurement.
In further pre-specified analyses of the primary out-
come, we explored the effects of programme attendance
via a “per protocol” analysis where attendance at all four
core group sessions was defined as a sufficient dose of
the programme, and using a complier average causal ef-
fect (CACE) analysis [49, 50]. We examined the moder-
ating effects of pre-specified baseline characteristics
(site, gender, age, ethnicity, baseline BMI, deprivation
index) on weight loss using regression models including
an intervention-subgroup interaction term [51]. We also
conducted an unplanned sensitivity analysis to examine
the effect of excluding an extreme outlier.
All statistical tests were two-sided, and deemed statis-
tically significant if p ≤ 0.05, with means and 95% confi-
dence intervals (CI) reported. We made no adjustment
for multiple testing because a primary outcome was pre-
specified, and the outcomes are correlated, so simple
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adjustment for the number of comparisons would be
overly conservative [52]. Data were analysed in STATA
version 14.2.
Service user involvement
The research built on prior work with service users [27] in-
cluding workshops to understand the priorities and informa-
tion needs of people at risk of diabetes [26]. Feedback from
early participants in the prototype LWTC programme [29]
confirmed prior to the trial that intervention burden and
measures were acceptable. Meetings were held at the begin-
ning and end of the study with a Public & Patient Involve-
ment group comprising up to five previous programme
participants. Two representatives of this group reviewed trial
documentation in detail, sat on the Trial Steering Commit-
tee and assisted with interpretation of findings.
Protocol amendments
During recruitment, inclusion criteria were modified to
allow recruitment outside Exeter and to increase the
upper age limit from 74 to 75 years to accommodate
participants turning 75 between referral and baseline as-
sessment. We also added collection of available
laboratory-based HbA1c test results from GP practice
databases for the year before and after baseline to allow
comparison to lower than anticipated point-of-care test
results.
Follow-up data on diagnoses (e.g. cancer) or co-
interventions (e.g. new medications, participation in
other weight loss programme) likely to affect weight,
were ultimately only collected at one of the sites, pre-
cluding planned sensitivity analyses examining the
effects of these factors on weight loss. Seven items
intended to measure depression in the existing service
evaluation [29] could not be scored due to lack of
correspondence with the original, validated measure
[53]. Finally, we adapted our original accelerometry
analysis plans to accommodate recently developed
processing methods for raw data [43]. Changes to the
protocol and Statistical Analysis Plan were approved
by the Trial Steering Committee.
Results
Participant flow (Fig. 1)
There was a 23% response rate to over 3000 invitations
sent from 17 GP practices. Forty-four percent of respon-
dents (314) were eligible, consented and randomised,
representing 10% of those invited (2 to 26% across prac-
tices). A further 123 respondents (17%) opted for referral
to the programme outside the trial.
Six-month primary outcome data were available for
285 (90% of intervention, 92% of control) participants. A
further eight (3%) provided self-reported weight. At 12-
months, 134 intervention participants (85%) provided
objective weight data. Those not providing primary out-
come data were similar to those providing data in terms of
key socio-demographic, socio-economic and clinical char-
acteristics except for being somewhat younger, and more
likely in paid employment (Additional file 3: Table S1).
Baseline characteristics
The randomisation produced balanced groups in terms of
the key characteristics of gender, age and BMI categories
overall (Table 1) and within each site (Additional file 3:
Tables S2a, S2b). However, there were more White British
participants and smokers in the intervention group, and
intervention participants were on average 0.9 kg heavier at
baseline. Since ethnicity was deemed to be potentially
prognostic of weight loss [54], sensitivity analyses were
conducted with adjustment for this as well as the planned
adjustment for baseline weight in the primary analysis.
There was good representation of men (44%), ethnic mi-
norities (26%) and people living in deprived areas (33% in the
two most deprived quintiles) in the sample, which comprised
mainly older (mean age 61.4 years), retired (48%), obese
adults (mean BMI 31.7) with existing long-term conditions
(73%), most commonly hypertension, high cholesterol and
musculoskeletal problems. Only 17% met recommendations
for 150min per week of moderate-vigorous physical activity
accumulated in bouts of at least 10min.
The mean sample HbA1c (39.8 mmol/mol) according
to trial point-of-care testing was below the 42–47 mmol/
mol range for non-diabetic hyperglycaemia, with only 87
participants (28%) having a point-of-care HbA1c result
in this range. However, 200 (92%) of 218 participants
(69% of total sample) for whom laboratory-based HbA1c
results were obtained from GP practices, had a record of
HbA1c in the non-diabetic hyperglycaemia range during
the prior year, with a mean (SD) of 43.9 (2.2).
The sample was representative of local populations,
with half of Birmingham participants [55] and 7% of
Exeter participants [56] from a non-White British back-
ground, and 58% overall (90% in Birmingham, 31% in
Exeter) living in areas with above average levels of
deprivation [57] (Additional file 3: Tables S2a, S2b).
Compared to UK population norms, self-rated health
(mean 73.9 on 0–100 scale) was somewhat lower (e.g.
mean 81.7 for 55–64, 77.3 for 65–74 age groups [58])
and well-being similar (mean 24.9 on 0–35 scale com-
pared to 23.6 for UK adults [33]).
Intervention delivery and attendance
Attendance data were received from providers for 135
intervention participants (86%), of whom 129 (82%) had
complete data on attendance at core group sessions
(Additional file 3: Table S3). Attendance at these de-
clined from 92% at session one to 81% at session four
with 68% of participants attending all four group
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Table 1 Participant characteristics at baseline (n (%) unless indicated)
Control
n = 157
unless indicated
Intervention
n = 157
unless indicated
Total sample
n = 314
unless indicated
Stratification & minimisation variables
Site Exeter 86 (55) 84 (54) 170 (54)
Birmingham 71 (45) 73 (47) 144 (46)
Gender (men) 69 (44) 68 (43) 137 (44)
Age categories 18–54 years 39 (25) 39 (25) 78 (25)
55–64 years 43 (27) 45 (29) 88 (28)
65–75 years 75 (48) 73 (47) 148 (47)
BMI categories 23–29.99 kg/m2= 65 (41) 64 (41) 129 (41)
30–36.99 kg/m2 72 (46) 72 (46) 144 (46)
37–45 kg/m2 20 (13) 21 (13) 41 (13)
Socio-demographic & socio-economic characteristics
Mean (SD) age (years) 61.29 (9.86) 61.46 (9.99) 61.38 (9.91)
Ethnicity White British 107 (68) 124 (79) 231 (74)
White other 10 (6) 2 (1) 12 (4)
Asian 26 (17) 20 (13) 46 (15)
Black 12 (8) 10 (6) 22 (7)
Mixed 2 (1) 1 (1) 3 (1)
Employment status Retired 73 (47) 79 (50) 152 (48)
Employed/self employed 65 (41) 56 (36) 121 (39)
Unemployed 12 (8) 13 (8) 25 (8)
Long-term sick/disabled 2 (1) 3 (2) 5 (2)
Carer 1 (1) 4 (3) 5 (2)
Other 4 (3) 2 (1) 6 (2)
Level of education Primary 5 (3)a 2 (1) 7 (2)b
Some secondary 5 (3)a 2 (1) 7 (2)b
Secondary to 16 years 52 (33)a 50 (32) 102 (33)b
Secondary to 18 years 10 (6)a 11 (7) 21 (7)b
Additional training 47 (30)a 59 (38) 106 (34)b
Undergraduate 24 (15)a 22 (14) 46 (15)b
Postgraduate 13 (8)a 11 (7) 24 (8)b
Median (IQR) Index of
Multiple Deprivation score (IMD)
20.38 (21.33) 19.42 (21.72) 19.75* (21.19)
IMD quintiles 1 most deprived 16 (10) 21 (13) 37 (12)
2 32 (20) 33 (21) 65 (21)
3 35 (22) 39 (25) 74 (24)
4 42 (27) 32 (20) 74 (24)
5 least deprived 32 (20) 32 (20) 64 (20)
Clinical characteristics
Any long term condition 114 (73) 115 (74)c 229 (73)d
Smoking 13 (8) 22a (14) 35b (11)
Disability 20 (13) 19 (12) 39 (12)
Mean (SD) weight (kg) 86.82 (13.37) 87.74 (16.76) 87.28 (15.14)
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sessions (79% in Exeter, 56% in Birmingham), and an
average of 3.4 sessions attended (3.7 in Exeter, 3.1 in
Birmingham). Those attending all group sessions were
significantly older, more likely to be White British, have
lower education levels and be from less deprived areas,
and less likely to be smokers than those missing sessions
(Additional file 3: Table S4).
Data on follow up support contacts had not been con-
sistently recorded by providers. Information on 2-, 3-
and 6-month contacts, primarily delivered in groups in
Exeter and via a mix of telephone (2 and 3months) and
groups (6 month) in Birmingham, were available for only
109 (69%), 91 (58%) and 53 (34%) participants, respect-
ively. Data on contacts beyond 6months were available
for only six (4%) participants.
Findings from primary analyses at six months
The main findings are presented in Table 2. The inter-
vention group on average lost 1.7 kg more weight be-
tween baseline and 6 months than the waiting list
control group (95% CI − 2.6 to − 0.9).
The prototype LWTC programme doubled the pro-
portion of participants achieving weight loss of 3 and 5%
of their body weight, with 33% of intervention
participants losing ≥3 and 21% losing ≥5%, compared to
16 and 8% of controls. There were significant differences
between groups in terms of reductions in BMI and waist
circumference, but not in HbA1c, blood pressure or ob-
jectively-measured moderate-vigorous physical activity.
In terms of self-reported outcomes, the intervention
group showed significantly greater decreases in scores
reflecting dietary behaviour related to fat intake and sig-
nificantly greater increases in scores reflecting fibre in-
take, as well as significantly greater improvements in
self-rated health status than controls. There were no sig-
nificant differences in life satisfaction or mental well-
being.
Findings from sensitivity and subgroup analyses at six
months
Findings in relation to the primary outcome were ro-
bust, ranging from − 1.5 to − 1.7 kg (CIs ranging from
− 2.6 to − 0.8) greater weight loss at 6 months amongst
participants in the intervention compared to control
arm when various approaches were employed to im-
pute missing weight data (Additional file 3: Table S5).
When analyses of clinical outcomes were additionally
adjusted for baseline between-group differences in
ethnicity (white British versus other) most differences
were slightly increased (e.g. adjusted mean difference
in weight loss = − 1.9 kg, CI − 2.8 to − 1.0; Additional
file 3: Table S6). Excluding an extreme outlier who
gained 20 kg in the intervention group similarly in-
creased between-group differences in weight loss
(mean difference − 1.9 kg, CI − 2.7 to − 1.1).
Differences in weight loss were greater in per protocol
analyses confined to intervention participants (n = 81,
57% of those with primary outcome data at 6 months)
attending all four group sessions (mean difference to
controls − 2.2 kg, CI − 3.1 to − 1.3) and in the CACE
analysis (mean difference − 3.0 kg, CI − 4.5 to − 1.5).
Moderator analyses (Table 3) suggested effects of the
programme on weight loss were similar across sites and
regardless of gender or area deprivation. Though no
between-subgroup differences were significant, those
aged under 55 years and with BMI < 30 kg/m2 showed
lower average weight loss (< 1 kg), and white British par-
ticipants lost more weight than other ethnicities.
Findings at 12months (Table 4)
There was a small, non-significant average weight re-
gain of 0.4 kg (CI − 0.2 to 0.9) amongst intervention par-
ticipants between 6 and 12 months, representing an
average weight loss of − 1.6 kg (CI − 2.5 to − 0.7) from
baseline to 12 months in the intervention arm, but with
only small numbers (6%) achieving 5% weight loss at 12
months. There was a small further reduction in waist
circumference but no significant changes in other ob-
jective or self-reported outcomes.
Adverse events
No serious adverse events were deemed to be related to
trial participation in either group. There were four non-
serious adverse events amongst intervention group par-
ticipants potentially related to the intervention, all short-
term injuries stemming from increased exercise (pelvic
pain, lower back pain, aggravation of existing sciatica,
Table 1 Participant characteristics at baseline (n (%) unless indicated) (Continued)
Control
n = 157
unless indicated
Intervention
n = 157
unless indicated
Total sample
n = 314
unless indicated
Mean (SD) HbA1c (mmol/mol)
from point-of-care test
39.69 (2.73) 39.88 (3.06) 39.79 (2.90)
HbA1c in non-diabetic hyperglycaemia range
(42–47mmol/mol) from point-of-care test
42 (27) 45 (29) 87 (28)
*Compared to 17.4 for England [57]
an = 156; bn = 313; cn = 155; dn = 312
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shoulder injury) that resolved on their own or with treat-
ment (e.g. physiotherapy, acupuncture). There were
none reported in the control group.
Discussion
Principal findings
Our results showed that the prototype LWTC voluntary
sector-led diabetes prevention programme successfully
engaged both men and women from a diverse and repre-
sentative sample of the population. In this real-world
setting, the programme generated an average 1.7 kg
weight loss at 6 months compared to usual care. It also
doubled the proportion of people losing ≥5% of their
baseline weight, though only 21% of intervention partici-
pants achieved this level of weight loss. In sensitivity
analyses, estimated effects on weight loss were robust to
Table 2 Primary intention-to-treat analyses of primary and secondary outcomes at 6 months for participants providing data
Waiting list control
group
Intervention group Between group
difference*
p-value
Baseline
n = 157
unless
indicated
6-months
n = 144
unless
indicated
Baseline
n = 157
unless
indicated
6-months
n = 141
unless
indicated
Mean (95% CI)
or odds ratio (OR)
(95% CI) where indicated
Primary outcome
Weight loss (kg) n/a −0.10
(3.03)
n/a −1.91
(4.49)
−1.72 (−2.59 to − 0.85) <0.001
Secondary weight-related outcomes
N (%) > 3% weight loss n/a 23
(16)
n/a 46
(33)
OR = 2.53 (1.41 to 4.52) 0.002
N (%) > 5% weight loss n/a 12
(8)
n/a 29
(21)
OR = 2.83 (1.36 to 5.90) 0.006
Mean (SD) BMI (kg/m2) 31.56
(4.39)
31.58
(4.60)
31.85
(4.66)
31.07
(4.53)
−0.64 (−0.95 to − 0.33) <0.001
Mean (SD) waist circumference (cm) 104.80
(11.28)
104.11
(11.48)
104.85
(12.62)
102.36
(12.50)
−1.36 (−2.36 to −0.36) 0.008
Other secondary objective outcomes
Mean (SD) HbA1c (mmol/mol) 39.69
(2.73)
40.18a
(3.22)
39.88
(3.06)
39.71
(5.70)
−0.76 (−1.73 to 0.21) 0.124
Mean (SD) blood pressure systolic (mmHg) 137.58
(18.82)
138.44
(17.20)
136.22
(17.10)
136.91
(17.48)
−0.51 (−3.69 to 2.67) 0.752
Mean (SD) blood pressure diastolic (mmHg) 79.83
(10.60)
79.85
(9.33)
78.97
(10.37)
78.21
(9.77)
−0.81 (−2.62 to 1.01) 0.383
Mean (SD) total mins moderate-vigorous
activity (MVPA) per week
318.67b
(176.07)
312.95c
(207.80)
337.34d
(189.12)
332.05e
(206.24)
−11.22 (−48.21 to 25.78) 0.551
Mean (SD) total mins MVPA in 10+ min bouts
per week
73.55b
(96.67)
79.57c
(127.99)
80.09d
(116.85)
82.45e
(130.36)
−8.23 (−30.92 to 14.46) 0.475
N (%) meeting recommendation for 150 mins
MVPA in 10+ min bouts per week
22b
(16)
20c
(19)
25d
(17)
20e
(18)
OR = 0.72 (0.31 to 1.68) 0.448
Secondary self-reported outcomes
Dietary behaviour fat subscale scores (0 to 3,
lower better)
1.95f
(0.39)
1.92g
(0.33)
1.94
(0.30)
1.81h
(0.33)
−0.11 (−0.18 to −0.05) 0.001
Dietary behaviour fibre subscale score (0 to 3,
higher better)
2.17f
(0.40)
2.19g
(0.42)
2.17
(0.38)
2.30h
(0.38)
0.12 (0.05 to 0.20) 0.001
Mean (SD) health rating (0–100, higher
better)
75.09i
(17.37)
73.65j
(18.49)
72.78k
(19.95)
77.24h
(16.66)
4.48 (0.85 to 8.11) 0.016
Mean (SD) life satisfaction rating (0–10, higher
better)
7.43i
(1.90)
7.48j
(1.96)
7.65
(2.03)
7.73h
(1.74)
0.14 (−0.18 to 0.46) 0.385
Mean (SD) mental well-being scores (0–35,
higher better)
24.88f
(5.09)
24.07h
(5.02)
24.82
(4.69)
24.99h
(3.89)
0.04 (−0.21 to 0.28) 0.761
*Mean differences, ORs and CIs adjusted for baseline outcome value, site, gender, age and baseline BMI category
an = 142, 2 participants missing HbA1c due to machine malfunction;
bn = 135, cn = 104, dn = 143, en = 112, with 4+ valid days, including a weekend day, of accelerometry data
fn = 154; gn = 141; hn = 140; in = 152; jn = 139; kn = 156
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missing data (ranging from 1.5–1.7 kg) and increased
when baseline differences, an extreme outlier and group
session attendance were considered (up to 3 kg in CACE
analysis). In observational follow-up of intervention par-
ticipants, effects on weight were maintained to some de-
gree at 12 months. The programme had no significant
effects on other clinical risk factors (HbA1c and blood
pressure), or moderate-to-vigorous physical activity, but
resulted in changes in self-reported health status and
dietary behaviours.
Findings in relation to other studies
The prototype LWTC programme recruited a high pro-
portion of men (44%) compared with previous studies of
weight loss in UK settings (which have recruited between
16 and 31% males [36, 37, 59]). The magnitude of weight
loss observed was similar to the 1.6 to 2.5 kg reported in
reviews of randomised controlled trials of real-world dia-
betes prevention interventions [15] and previous UK-
based diabetes prevention studies [16, 17], though less
than the 3-4 kg that might be expected for programmes
fully implementing NICE guidance on the content of dia-
betes prevention interventions [15]. Reasons for this may
include lower than planned contact time (data on contacts
outside core group sessions were not consistently re-
corded), or variations from planned delivery (fidelity was
checked only in a sub-sample at one site [28]).
Since the weight change in our control group was close
to zero and trial eligibility criteria and sample characteris-
tics were almost identical to those of the NHS DPP, our
data provide some confidence that the clinically meaning-
ful weight loss (3.2 kg) observed for participants with high
levels of attendance at NHS DPP sessions [14] is an accur-
ate estimate. This estimate is also broadly consistent with
our CACE analysis, which estimated a 3 kg weight loss for
people attending all four core programme sessions.
The lack of effects on physical activity is a particular
concern, given that a substantial proportion of programme
time was devoted to promoting activity. Methods for en-
hancing physical activity in the prototype LWTC and
similar programmes therefore need to be examined and, if
necessary, refined in the light of what has been successful
in other studies [18].
Strengths and weaknesses
This is the first trial of a voluntary sector-led diabetes
prevention intervention in the UK. Strengths included
the fully-powered randomised controlled trial design,
Table 3 Moderating effects of key baseline characteristics on weight loss (primary outcome) at 6 months (n = 285)a
Between group differenceb
Mean (95% CI)
Interaction term
p value
Site 0.829
Exeter (n = 151) −1.77 (−3.07 to − 0.46)
Birmingham (n = 134) −1.59 (−2.71 to − 0.48)
Gender 0.508
Male (n = 124) −1.87 (−3.43 to −0.31)
Female (n = 161) −1.43 (−2.40 to −0.45)
Age (yrs) 0.501
<55 (n = 66) −0.75 (−2.92 to 1.42)
55–65 (n = 83) −1.87 (−3.39 to − 0.36)
65–75 (n = 136) −2.16 (− 3.30 to − 1.02)
Baseline BMI (kg/m2) 0.101
23.0–29.9 (n = 118) −0.79 (− 1.91 to 0.34)
30.0–36.9 (n = 130) −1.99 (−3.36 to − 0.63)
37.0–45.0 (n = 37) −2.67 (−6.07 to 0.72)
Ethnicity 0.562
White British (n = 211) −2.03 (−3.09 to −0.96)
Other (n = 74) −1.10 (−2.65 to 0.45)
Deprivation 0.643
Low (≤ England median IMD score) (n = 116) −1.97 (−3.29 to −0.65)
High (> England median IMD score) (n = 169) −1.52 (−2.71 to −0.33)
abased on intention-to-treat completers
bAdjusted for baseline outcome value, site, age, gender and baseline BMI
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real-world setting, use of objective and independently
assessed outcomes, high follow-up rates and representa-
tiveness of the study sample, including a high proportion
of men, people from ethnic minority groups, and living
in deprived areas. The findings are therefore likely to be
reflective of programme performance across a range of
UK locations.
Limitations included the 10% recruitment rate (which
though it reduces the generalisability of findings is not
atypical for such trials), the short (6 month) follow-up
for comparative analyses due to ethical and practical
constraints on the design, lack of blinding of data collec-
tors (though objective measures were used) and incom-
plete attendance data. The wide variability in some effect
estimates and a lack of power means that we cannot ex-
clude the potential for effects on secondary outcomes
(e.g. the sample size provided 80% power to detect
changes of 66 min/week in MVPA and 1.4 mmol/mol in
HbA1c), and differences in weight loss between partici-
pant sub-groups. Given the 7-month recruitment period,
there is potential for seasonal effects on outcomes in
both groups, however, this would not affect the main
between-group comparison. It should also be noted that
the prototype LWTC programme evaluated here has
been substantially upgraded since the study, partly in re-
sponse to our findings and to meet NHS DPP require-
ments [20], including expanding the number of initial
sessions from four to seven, increasing the total number
of formal contacts to 13 and placing greater emphasis
on physical activity (e.g. mapping and discussing local
opportunities to engage in ongoing physical activity, sup-
porting enrolment in, and the development of new,
walking groups). Hence, the programme’s performance
may have been improved and ongoing evaluation is un-
derway [14].
Explanations and implications for clinicians and
policymakers
The impact of individual-level health promotion inter-
ventions on health inequalities is often raised as a key
public health policy question [23]. This study has shown
that it is possible, through a voluntary sector delivery
model, to recruit and engage both men and women with
above average (for England) area deprivation scores and
from a range of ethnic backgrounds. Moderation ana-
lyses showed that the effects of the prototype LWTC
programme at 6 months were not significantly different
across sites or population subgroups and extended to
Table 4 Maintenance of changes between 6- and 12-months amongst intervention participants with data at both timepoints
6 months
n = 134
unless indicated
12months
n = 134
unless indicated
Mean change
(95% CI)
p value
Primary outcome
Mean (SD) weight (kg) 85.52 (16.54) 85.88 (17.01) 0.36 (−0.20 to 0.91) 0.206
Secondary weight-related outcomes
N (%) > 3% weight loss from baseline 45 (34) 15 (11) N/A
N (%) > 5% weight loss from baseline 28 (21) 8 (6) N/A
Mean (SD) BMI (kg/m2) 31.16 (4.60) 31.28 (4.78) 0.13 (−0.08 to 0.33) 0.239
Mean (SD) waist circumference (cm) 102.46a (12.67) 101.96a (12.59) −0.64 (−1.29 to 0.00) 0.051
Other secondary objective outcomes
Mean (SD) HbA1c (mmol/mol) 39.32a (2.65) 39.52a (3.09) 0.20 (−0.30 to 0.69) 0.438
Mean (SD) BP systolic (mmHg) 136.95a (17.11) 137.91a (19.28) 0.96 (−1.54 to 3.47) 0.448
Mean (SD) BP diastolic (mmHg) 77.90a (9.83) 78.30a (11.25) 0.40 (−1.02 to 1.82) 0.579
Mean (SD) total mins moderate-vigorous activity (MVPA) per week 344.87b (221.54) 355.06b (247.65) 10.18 (−23.01 to 43.39) 0.544
Mean (SD) total mins MVPA in 10+ min bouts per week 92.88b (140.75) 84.78b (137.82) −8.09 (−28.34 to 12.15) 0.429
N (%) meeting recommendation for 150 mins MVPA in 10+ min
bouts per week
17b (20) 13b (15) NA
Secondary self-reported outcomes
Dietary behaviour fat subscale scores (0 to 3, lower better) 1.81c (0.34) 1.83c (0.31) 0.02 (−0.02 to 0.07) 0.362
Dietary behaviour fibre subscale score (0 to 3, higher better) 2.30c (0.37) 2.28c (0.39) −0.03 (− 0.08 to 0.02) 0.293
Mean (SD) health rating (0–100, higher better) 77.34c (16.71) 78.34c (16.74) 1.00 (−1.74 to 3.74) 0.472
Mean (SD) life satisfaction rating (0–10, higher better)) 7.74b (1.75) 7.84b (1.58) 0.10 (−0.15 to 0.34) 0.425
Mean (SD) mental well-being scores (0–35, higher better) 27.26d (4.91) 27.57d (4.57) 0.32 (−0.34 to 0.98) 0.342
an = 133; bn = 87; cn = 130; dn = 129
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men, older adults, those with BMI in the obese range
and those living in areas of above average deprivation.
Although, we were unable to assess cost-effectiveness, a
Social Return on Investment Analysis conducted as part
of the wider evaluation of the programme estimated the
cost at £296.95 per participant and that for every £1
invested, there was a social return of around £5.80 over
a 3 year period [60].
An unanticipated finding was that based on point-of-
care testing only 28% of participants had HbA1c in the
non-diabetic hyperglycaemia range at baseline, despite
available GP records confirming that over 90% had re-
cent laboratory-tested HbA1c in the eligible range on re-
ferral. The mismatch could be explained by a tendency
for point-of-care testing machines (which are not diag-
nostic tools [61]) to under-estimate HbA1c. Alternatively,
there could be “diagnostic drift” between laboratory mea-
sures and baseline testing. In either case, this is an import-
ant participation-selection issue for large-scale diabetes
prevention programmes. Previous research has also raised
concerns about inconsistency between different methods
for identifying people who are at risk of developing dia-
betes [62]. One approach to improving selection would be
to require a second, confirmatory test (using the same
method) and/or a higher cut-off for eligibility, to ensure
that people entering the programme are truly “high risk”.
Unanswered questions and future research
Further research is needed to establish robust, pragmatic
criteria for identifying people at risk of type 2 diabetes,
and to establish cost-effective methods for increasing
physical activity and sustaining weight loss in real-world
diabetes prevention programmes. We also urgently need
research on alternative options for the high proportion
of people who do not respond to invitations (up to 90%),
choose not to attend (52%), or do not adhere sufficiently
(around 50%) to available lifestyle interventions. Further-
more, work is needed to assess the in-service effective-
ness of the upgraded LWTC programme and to identify
and address any differential effects of current diabetes
prevention programmes across population subgroups to
minimise health inequalities.
Conclusion
This study contributes to the limited base of robust
evidence available on the “real-world” effectiveness of
community-based diabetes prevention interventions in the
UK, particularly voluntary sector-led programmes. Overall,
our results confirm claims that voluntary sector-led pro-
grammes can reach a wide and diverse range of the
population and show that the prototype LWTC
programme had modest short-term effects on weight-
related outcomes, including similar effects across popu-
lation sub-groups who often fail to engage with other
programmes. However, it had limited effects on other
diabetes risk factors including physical activity. To
maximise the impact on future diabetes incidence, simi-
lar diabetes prevention programmes may need to refine
eligibility-testing procedures to appropriately target in-
dividuals at highest risk of diabetes, improve methods
for supporting physical activity, and find ways to maxi-
mise programme attendance/contact time (which medi-
ates weight loss) and the maintenance of any lifestyle
changes generated.
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